Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
KemPharm, Inc. KMPH
$5.81
На 18:00, 12 мая 2023
+72.12%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
200473469.00000000
-
week52high
6.92
-
week52low
4.00
-
Revenue
10458000
-
P/E TTM
-5
-
Beta
2.15864700
-
EPS
-0.91000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 17 авг 2022 г. |
| HC Wainwright & Co. | Buy | Neutral | 31 янв 2022 г. |
| HC Wainwright & Co. | Neutral | Neutral | 09 апр 2021 г. |
| HC Wainwright & Co. | Neutral | Buy | 04 мар 2021 г. |
| Roth Capital | Buy | 25 янв 2021 г. | |
| Canaccord Genuity | Buy | 15 сент 2022 г. | |
| Cantor Fitzgerald | Overweight | 17 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Pascoe Richard W | A | 19973 | 9500 | 13 янв 2023 г. |
| Clifton R. LaDuane | A | 9277 | 25 | 13 янв 2023 г. |
| Clifton R. LaDuane | A | 9252 | 610 | 13 янв 2023 г. |
| Clifton R. LaDuane | A | 459726 | 459726 | 09 янв 2023 г. |
| Schafer Joshua | A | 300000 | 300000 | 09 янв 2023 г. |
| Guenther Sven | A | 306000 | 306000 | 09 янв 2023 г. |
| Mickle Christal M M | A | 300000 | 300000 | 09 янв 2023 г. |
| Sangiovanni Timothy J. | A | 136986 | 136986 | 09 янв 2023 г. |
| Pascoe Richard W | A | 700000 | 700000 | 09 янв 2023 г. |
| Clifton R. LaDuane | A | 8109 | 400 | 30 сент 2022 г. |
Новостная лента
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
GlobeNewsWire
27 февр 2023 г. в 07:30
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022.
KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating
Seeking Alpha
03 февр 2023 г. в 10:03
We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined >40%, and now the stock is trading at an attractive enterprise value of $130m. AZSTARYS targeting ADHD has been approved, and it no longer contributes much to the stock price at this point. Arimoclomol targeting NPC is the next focus.
KemPharm, Inc. (KMPH) Q3 2022 Earnings Call Transcript
Seeking Alpha
09 ноя 2022 г. в 22:01
KemPharm, Inc. (NASDAQ:KMPH ) Q3 2022 Results Conference Call November 9, 2022 5:00 PM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Travis Mickle - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Conference Call Participants Sumant Kulkarni - Canaccord Jonathan Aschoff - Roth Capital Partners Operator Good afternoon, and welcome to the KemPharm Third Quarter 2022 Corporate and Financial Results Conference Call. Currently, all callers have been placed in a listen-only mode and following management's prepared remarks, the call will be opened up for questions.
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
Zacks Investment Research
29 сент 2022 г. в 12:47
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
01 сент 2022 г. в 07:30
CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference being held from September 12-14, 2022, in New York, New York. In addition, management will be available for virtual one-on-one investor meetings during the conference.